Dimension Therapeutics Inc (DMTX) was Initiated by Cantor Fitzgerald to “Buy” and the brokerage firm has set the Price Target at $32. Cantor Fitzgerald advised their investors in a research report released on Jun 3, 2016.
Many Wall Street Analysts have commented on Dimension Therapeutics Inc. Dimension Therapeutics Inc was Initiated by Jefferies to “Buy” on Jun 2, 2016. Dimension Therapeutics Inc was Downgraded by Goldman to ” Neutral” on Mar 30, 2016.
On the company’s financial health, Dimension Therapeutics Inc reported $-0.43 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Dec 4, 2015. Analyst had a consensus of $-0.52. The company had revenue of $2.10 million for the quarter, compared to analysts expectations of $1.73 million. The company’s revenue was up 75.0% compared to the same quarter last year.
In a different news, on Oct 29, 2015, Michael Dybbs (director) purchased 961,538 shares at $13.00 per share price.
Dimension Therapeutics Inc. is a United States-based gene therapy company focused on developing novel treatments for rare diseases. The Company is focused on developing treatments for hemophilia A hemophilia B and rare genetic diseases. The Company’s adeno-associated virus (AAV) vector technology enables for systemic administration of the gene therapy in vivo for the treatment of an array of single-gene rare diseases. The Company is conducting pre-clinical development activities for its program in hemophilia A. The Company also has access to NAV vector technology in a range of rare disease indications.